A current-rule compliance map for drug establishment registration, listing, annual certification, and 510(j)(3) drug amount reporting ahead of FDA’s September 29, 2026 CDER SBIA workshop, with the future 12-digit NDC timeline kept clearly separate.
Evidence tags used below:
Current rule
Guidance
Attributed event
Inference
Future event
Unknown
1. Executive Summary: Pre-Workshop Registration and Listing Baseline
If you manufacture, prepare, or import a drug for commercial distribution in the United States, the obligations you must satisfy now are distinct from the future 12-digit National Drug Code (NDC) conversion. This article separates the two so you can act on current duties without confusing them with long-horizon planning.
Current rule Establishments must register, list their drugs, keep listings updated, and complete annual listing certification under 21 CFR Part 207 and FD&C Act Section 510. These are ongoing, immediately applicable duties.
Current rule Drug amount reporting under FD&C Act Section 510(j)(3) is also a current obligation. It was added by the CARES Act, specifically section 3112(e) — not section 505(j)(3)(B). That authority distinction matters for citing the correct statutory basis in submissions.
Future event The 12-digit NDC final rule was published March 5, 2026, but it carries a seven-year delayed effective date and a subsequent three-year transition period. It is a future implementation planning item, not an immediate 2026 labeling requirement.
| If you need to… | Do this now (current rule) | Plan separately (future) |
|---|---|---|
| Register an establishment | Submit via EDRLS / SPL under 21 CFR Part 207 | Track NDC format rule, not a 2026 label change |
| List or update a drug | Keep SPL listing current; certify annually | Map current 10-digit NDCs for future conversion |
| Report drug amounts | Report under FD&C Act 510(j)(3), added by CARES Act section 3112(e) | No NDC-format impact on amount reporting today |
| Avoid deficiency letters | Validate submissions in FDA Direct; correct SPL errors | Attend Sept 29, 2026 workshop for updates |
2. Workshop Overview: Sept 29, 2026 CDER SBIA Event Details & Scope
Attributed event FDA’s Center for Drug Evaluation and Research (CDER) Small Business and Industry Assistance (SBIA) program will host the FDA’s Drug Registration and Listing Workshop: Compliance, Regulatory and Submission Updates on September 29, 2026, from 8:45 a.m. to 4:00 p.m. ET. The event is hybrid: in person at the FDA White Oak Campus (10903 New Hampshire Ave, Building 31, The Great Room, Silver Spring, MD 20903) and virtual via Adobe Connect. Workshop details are available on the FDA workshop page (content current as of 07/20/2026).
Attributed event Per the official agenda, the workshop will cover the latest updates for submitting accurate registration and listing data to avoid submission errors, deficiency letters, and manual overrides; drug amount reporting requirements and compliance outcomes; and an in-depth panel on the March 5 final rule revising the NDC format, including the future format of the NDC.
Attributed event The intended audience includes regulatory science and regulatory affairs professionals working on establishment registration and drug listing; consultants and vendors assisting with SPL submissions; healthcare professionals using drug listing data; and foreign drug manufacturers and importers that manufacture and import drugs for U.S. commercial distribution. FDA encourages attendees to review tutorials in FDA Direct before the event.
Unknown The workshop outcomes, any policy clarifications, and any validation-rule updates have not yet been announced. This article does not predict them.
3. Core Registration & Listing Obligations under 21 CFR Part 207 & FD&C Act 510
Current rule Drug establishment registration and drug listing are governed by 21 CFR Part 207 and FD&C Act Section 510. The operational duties that apply today fall into a clear set of recurring actions:
- Establishment registration — register each facility that manufactures, prepares, compounding, or processes a drug for commercial distribution.
- Drug listing — list each marketed drug in SPL format.
- Listing updates — update listing data when content changes (e.g., labeling, product scope, business operations).
- Annual listing certification — certify each year that listing information is current and accurate.
- Drug amount reporting — report amounts distributed under FD&C Act Section 510(j)(3) (see Section 4).
Guidance Submissions are made electronically through the Electronic Drug Registration and Listing System (EDRLS) using Structured Product Labeling (SPL). The Electronic Drug Registration and Listing Instructions describe how to prepare and submit SPL files and how to use FDA Direct for tutorials and validation.
Inference Because the workshop agenda foregrounds “current validation rules” and avoidance of submission errors, the most reliable pre-workshop posture is to fix data quality in SPL submissions now rather than wait for the event to reveal new requirements.
4. Drug Amount Reporting Requirements (FD&C Act Section 510(j)(3))
Current rule Listed-drug manufacturers and biological product manufacturers must report the amount of each listed drug distributed. The statutory authority is FD&C Act Section 510(j)(3).
Current rule This reporting requirement was added by the CARES Act, section 3112(e) — not section 505(j)(3)(B). When documenting your compliance basis, cite 510(j)(3) together with CARES Act section 3112(e). The 505(j)(3)(B) attribution is incorrect and should not be used.
Guidance FDA has issued guidance on this duty: Reporting Amount of Listed Drugs and Biological Products under Section 510(j)(3) of the FD&C Act. The guidance describes how to report amounts of listed drugs and biological products. Review it on the FDA guidance page.
Inference Drug amount reporting is operationally independent from the future NDC format change. Treat it as a current compliance stream; do not bundle its deadlines with the 12-digit NDC timeline.
5. The 12-Digit NDC Final Rule (March 5, 2026): What Manufacturers Need to Know
Future event On March 5, 2026, FDA published the final rule Revising the National Drug Code Format and Drug Label Barcode Requirements in the Federal Register. Read it on the Federal Register final rule page.
Future event The rule does not require immediate 2026 labeling changes. It provides a seven-year delayed effective date and, following that effective date, a three-year transition period. In approximate calendar terms, that places the effective date around 2033 and the end of the transition period around 2036; the rule’s own dates govern and should be confirmed in the Federal Register text.
Inference The correct framing for manufacturers is implementation planning, not a 2026 action item. Reasonable planning steps include inventorying current 10-digit NDCs, identifying label and barcode touchpoints, and tracking FDA guidance — without disrupting current registration and listing cycles.
| Current rule compliance (apply now) | Future NDC implementation planning (not a 2026 labeling requirement) |
|---|---|
| Register establishment; list drugs; keep updates current | Inventory current NDCs and label/barcode dependencies |
| Annual listing certification | Track seven-year delayed effective date (~2033) |
| 510(j)(3) drug amount reporting (CARES Act section 3112(e)) | Plan for three-year transition period after effective date (~2036) |
| Validate SPL submissions in FDA Direct / EDRLS | Monitor FDA guidance and workshop updates |
6. Common SPL Submission Errors, Deficiency Letters, and FDA Direct Portal Validation
Attributed event The workshop agenda explicitly lists submission errors, deficiency letters, and manual overrides as recurring problems. This signals that data quality in SPL submissions remains the dominant operational risk ahead of the event.
Guidance FDA Direct provides tutorials, webinars, and training videos. From the FDA Direct Home Page Quick Links, select Tutorials > Webinars > Training Videos for submission walkthroughs. The Electronic Drug Registration and Listing Instructions detail EDRLS submission mechanics.
Practical pre-workshop checklist for submission health:
- Confirm establishment registration data is current before listing updates.
- Validate SPL files against current validation rules; do not rely on outdated templates.
- Reconcile NDC, labeling, and product scope fields to avoid deficiency letters.
- Track any deficiency letters and manual overrides to identify recurring root causes.
- Confirm the correct statutory basis for amount reporting: 510(j)(3) via CARES Act section 3112(e).
Inference Submission accuracy is the single highest-leverage pre-workshop action because it is fully within an establishment’s control and independent of any future policy change.
7. Blocked Claims & Regulatory Uncertainty Boundaries
To stay within the approved scope, this article deliberately does not make the following claims:
- It does not predict the outcomes of the September 29, 2026 workshop.
- It does not promise automatic compliance or immunity from deficiency letters.
- It does not claim the workshop alters statutory annual listing certification deadlines.
- It does not describe the 12-digit NDC conversion as an immediate 2026 labeling requirement, and it does not omit the transition period.
Unknown Specifics that remain uncertain include the exact validation-rule updates to be discussed at the workshop, any clarifications on drug amount reporting enforcement, and any implementation sub-deadlines within the transition window. These will be addressed only after FDA publishes post-workshop outcomes.
Scope Disclaimer
This article is a pre-workshop compliance map based on four regulator-primary sources. It reflects rules and guidance current as of 2026-07-31. It is intended for manufacturers, regulatory affairs professionals, and submission consultants. It is not medical advice and does not address clinical decision-making. Statutory and regulatory text controls in all cases; verify against the primary sources below and the official Federal Register and FDA pages.
Sources
- FDA’s Drug Registration and Listing Workshop: Compliance, Regulatory and Submission Updates – 09/29/2026 — U.S. Food and Drug Administration (content current as of 07/20/2026).
- Revising the National Drug Code Format and Drug Label Barcode Requirements — Federal Register final rule, published March 5, 2026.
- Reporting Amount of Listed Drugs and Biological Products under Section 510(j)(3) of the FD&C Act — U.S. Food and Drug Administration guidance.
- Electronic Drug Registration and Listing Instructions — U.S. Food and Drug Administration (EDRLS).